Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: A SEER analysis

World Journal of Urology

Volumn 31, Issue 6, 2013, Pages 1535-1539

  Tsao, Che kai ^a   Small, Alexander C ^a   Kates, Max ^a   Moshier, Erin L ^a   Wisnivesky, Juan P ^a   Gartrell, Benjamin A ^a   Sonpavde, Guru ^b,c   Godbold, James H ^a   Palese, Michael A ^a   Hall, Simon J ^a   Oh, William K ^a   Galsky, Matthew D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cytoreductive nephrectomy; Disparities; SEER; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

ENZYME INHIBITOR; VASCULOTROPIN RECEPTOR;

AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; DRUG ANTAGONISM; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; PATHOLOGY; REGISTER; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME; UNITED STATES; UTILIZATION REVIEW;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEPHRECTOMY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REGISTRIES; RETROSPECTIVE STUDIES; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84888288039     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-1001-3     Document Type: Article

References (23)

1. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1: CD001425.
2. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J (1995) Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 154: 32-34.
3. Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP (1998) Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol 159: 1168-1173.
4. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659.
5. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970.
6. Jeldres C, Baillargeon-Gagne S, Liberman D et al (2009) A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. Urology 74: 837-841.
7. Tsao C-K EM, Small AC, Sonpavde G, Godbold J, Oh WK, Galsky MD (2012) Cytoreductive nephrectomy in the United States: patterns of care and patient characteristics. In: ASCO genitourinary cancers symposium, San Franscisco, California, USA.
8. O'Malley RL, Brewer KA, Hayn MH et al (2011) Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78: 595-600.
9. Richey SL, Culp SH, Jonasch E et al (2011) Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22: 1048-1053.
10. Sun M, Abdollah F, Schmitges J et al (2012) Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. BJU Int 109(12): 1807-1812.
11. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR (2008) Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 179: 1704-1708.
12. Vaishampayan UN, Do H, Hussain M, Schwartz K (2003) Racial disparity in incidence patterns and outcome of kidney cancer. Urology 62: 1012-1017.
13. Newman LA, Carolin K, Simon M et al (2001) Impact of breast carcinoma on African-American women: the Detroit experience. Cancer 91: 1834-1843.
14. Hoffman RM, Gilliland FD, Eley JW et al (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93: 388-395.
15. Cooper-Patrick L, Gallo JJ, Gonzales JJ et al (1999) Race, gender, and partnership in the patient-physician relationship. JAMA 282: 583-589.
16. Whitson JM, Reese AC, Meng MV (2011) Factors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus. BJU Int 107: 729-734.
17. Hellenthal NJ, Chamie K, Ramirez ML, deVere White RW (2009) Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma. J Urol 181: 1013-1018; discussion 8-9.
18. Abdollah F, Sun M, Thuret R et al (2011) Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol 18: 2988-2996.
19. You D, Jeong IG, Ahn JH et al (2011) The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol 185: 54-59.
20. Choueiri TK, Xie W, Kollmannsberger C et al (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185: 60-66.
21. Zini L, Capitanio U, Perrotte P et al (2009) Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 73: 342-346.
22. Wood CG, Margulis V (2009) Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 115: 2355-2360.
23. Chapin BF, Delacroix SE Jr, Culp SH et al (2011) Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60: 964-971.